<DOC>
	<DOCNO>NCT02720523</DOCNO>
	<brief_summary>A Phase 2b/3 , Randomized , Double-Blind Study Comparing ABT-494 Placebo Japanese Subjects Moderately Severely Active Rheumatoid Arthritis Who Are Stable Dose Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs ( csDMARDs ) Have Inadequate Response csDMARDs .</brief_summary>
	<brief_title>A Study Compare ABT-494 Placebo Subjects With Rheumatoid Arthritis ( RA ) Who Are Stable Dose Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs ( csDMARDs ) Have Inadequate Response csDMARDs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Diagnosis Rheumatoid Arthritis ( RA ) &gt; = 3 month also fulfill 2010 American College Rheumatology ( ACR ) /European League Against Rheumatism ( EULAR ) classification criterion RA . Subjects receive conventional synthetic diseasemodifying antirheumatic drug ( csDMARD ) therapy &gt; = 3 month stable dose &gt; = 4 week prior first dose study drug . Subject &gt; = 6 swollen joint ( base 66 joint count ) &gt; = 6 tender joint ( base 68 joint count ) Screening Baseline Visits . Subjects prior exposure one biological diseasemodifying antirheumatic drug ( bDMARD ) may enrol ( 20 % total number subject ) require washout period . Specifically , prior enrollment : 1 . Subjects limited exposure bDMARD ( &lt; 3 month ) OR 2 . Subjects respond bDMARD therapy discontinue due intolerability ( regardless treatment duration ) . Prior exposure Janus kinase ( JAK ) inhibitor Subjects consider inadequate responder ( lack efficacy ) bDMARD therapy , minimum 3 month treatment , determine Investigator . History arthritis onset prior age 17 year current diagnosis inflammatory joint disease RA ( include limit gout , systemic lupus erythematosus , psoriatic arthritis , axial spondyloarthritis [ SpA ] include ankylose spondylitis nonradiographic axial SpA , reactive arthritis , overlap connective tissue disease , scleroderma , polymyositis , dermatomyositis , fibromyalgia [ currently active symptom ] ) . Current diagnosis secondary Sjogren 's Syndrome permit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>ABT-494</keyword>
	<keyword>Antirheumatic agent</keyword>
	<keyword>Japanese</keyword>
</DOC>